Download PDF

1. Company Snapshot

1.a. Company Description

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide.It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes.


In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings.Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices.Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets.


The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers.It serves a range of customers, including healthcare providers, patients, and manufacturers.The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Show Full description

1.b. Last Insights on CTEC

ConvaTec Group Plc's recent struggles can be attributed to its disappointing Q2 2025 earnings release, which fell short of analyst expectations. The company's weak performance was driven by declining sales in its Advanced Wound Care segment, which accounts for a significant portion of its revenue. Additionally, ConvaTec's high debt levels and increasing interest expenses may be weighing on its financial performance.

1.c. Company Highlights

2. ConvaTec's 2025 Earnings: A Strong Performance with Growth Acceleration

ConvaTec reported a robust financial performance for 2025, with organic revenue growth of 6.4%, excluding InnovaMatrix, and operating margin expansion of 110 basis points to 22.3%. The company's EPS growth was 16%, with strong cash flow and a free cash to equity conversion of 101%. The actual EPS came out at $0.07156, slightly below estimates of $0.07423. The company's financial results demonstrate a strong track record of delivery, with double-digit EPS growth for the second year in a row.

Publication Date: Feb -25

📋 Highlights
  • Organic Revenue Growth: Achieved 6.4% growth in 2025, with guidance for 5-7% in 2026, excluding InnovaMatrix.
  • Margin Expansion: Operating margin increased 110 bps to 22.3% in 2025, targeting 23% in 2026 and mid-20s by 2027.
  • EPS Growth: Delivered 16% EPS growth in 2025, with double-digit growth expected in 2026 and 2027.
  • Free Cash Flow: Generated 101% free cash flow to equity conversion in 2025, targeting ~100% in 2026 for shareholder returns.
  • InnovaMatrix Rebound: Guided $20M sales in 2026, with volume growth expected from expanded geographic reach and new indications.

Segment Performance

The company's growth is driven by its four chronic care categories, which are structurally independent of the economic cycle. In 2026, ConvaTec expects mid-single-digit growth in Wound Care, Ostomy Care, and Continence Care, driven by new product launches, including ConvaNiox, ConvaFiber, and ConvaVac in Wound Care, and Esteem Body in Ostomy Care. Infusion Care is expected to grow at a high single-digit rate, driven by strong demand and the ability to service all types of pump technologies.

Guidance and Outlook

ConvaTec has increased its target growth rate to 6% to 8% per annum from 2027, driven by the successful launch of new products and a broadening pipeline. The company expects operating margin to reach at least 23% in 2026, with further progress in the second half. EPS growth is expected to be double-digit, driven by accelerating top-line growth. The company's guidance for InnovaMatrix sales is $20 million in 2026, driven by volume growth and a wider geographic scope.

Valuation

ConvaTec's current valuation metrics indicate a P/E Ratio of 31.37, EV/EBITDA of 13.48, and a Dividend Yield of 2.06%. The company's ROE is 12.38%, and ROIC is 8.3%. These metrics suggest that the market is pricing in a certain level of growth, but the company's accelerating top-line growth and expanding margins could potentially drive further upside.

Key Drivers and Risks

The key drivers of ConvaTec's growth include the successful launch of new products, a broadening pipeline, and a strong track record of delivery. Risks include the uncertainty surrounding InnovaMatrix sales, potential competition, and regulatory risks, including the FDA warning letter. However, the company is working to address these risks, and its clear capital allocation priorities and focus on investing organically should support its growth trajectory.

3. NewsRoom

Card image cap

FTSE 100 Live: London stocks pare gains; US futures point to mixed start

Dec -12

Source: proactiveinvestors.com

Card image cap

FTSE 100 Live: London stocks off to a strong start after Dow hits new record

Dec -12

Source: proactiveinvestors.com

Card image cap

Are Investors Undervaluing ConvaTec Group PLC (LON:CTEC) By 36%?

Nov -25

Source:

Card image cap

Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation

Nov -17

Source:

Card image cap

Stocks struggle despite manufacturing improvement

Nov -03

Source:

Card image cap

Stigma, Not Condition, Is the Biggest Barrier for 1 in 3 People Living With Chronic Conditions, According to New Convatec Research

Oct -27

Source:

Card image cap

Has ConvaTec Group PLC's (LON:CTEC) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Oct -23

Source:

Card image cap

How Recent Developments Are Shaping the ConvaTec Group Investment Story

Oct -06

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.60%)

6. Segments

Advanced Wound Care

Expected Growth: 6.5%

ConvaTec's Advanced Wound Care segment growth is driven by increasing demand for chronic wound management, rising prevalence of diabetes and obesity, growing adoption of advanced wound care technologies, and expansion into emerging markets. Additionally, strategic acquisitions and investments in R&D have enhanced the company's product portfolio, further fueling growth.

Ostomy Care

Expected Growth: 6.2%

ConvaTec's Ostomy Care segment growth of 6.2% is driven by increasing prevalence of chronic diseases, advancements in ostomy products, and rising awareness about ostomy care management. Additionally, strategic acquisitions, expansion into emerging markets, and a growing demand for home healthcare services contribute to the segment's growth.

Continence Care

Expected Growth: 6.8%

ConvaTec's Continence Care segment growth of 6.8% is driven by increasing demand for catheters and ostomy care products, fueled by an aging population and rising prevalence of chronic diseases. Additionally, expansion into emerging markets, product innovation, and strategic acquisitions contribute to the segment's growth.

Infusion Care

Expected Growth: 7.2%

ConvaTec's Infusion Care segment growth of 7.2% is driven by increasing demand for home infusion therapies, expansion in emerging markets, and strategic product launches. Additionally, the segment benefits from a growing elderly population, rising prevalence of chronic diseases, and a shift towards outpatient care, leading to increased adoption of infusion care products.

Hospital Care

Expected Growth: 6.9%

ConvaTec Group Plc's Hospital Care segment growth of 6.9% is driven by increasing demand for advanced wound care products, expansion into emerging markets, and strategic partnerships with healthcare providers. Additionally, investments in research and development have led to innovative product launches, further boosting growth.

7. Detailed Products

Ostomy Care

ConvaTec's Ostomy Care products are designed to help individuals with ostomies manage their condition with confidence and discretion. The range includes one-piece and two-piece pouching systems, skin barriers, and accessories.

Wound Therapeutics

ConvaTec's Wound Therapeutics products are designed to promote wound healing and tissue repair. The range includes dressings, gels, and other topical treatments.

Continence and Critical Care

ConvaTec's Continence and Critical Care products are designed to help individuals manage urinary incontinence and other urological conditions. The range includes catheters, drainage bags, and other accessories.

Infusion Devices

ConvaTec's Infusion Devices are designed to provide safe and reliable infusion therapy for patients. The range includes infusion sets, syringes, and other accessories.

8. ConvaTec Group Plc's Porter Forces

Forces Ranking

Threat Of Substitutes

ConvaTec Group Plc operates in the medical technology industry, which is characterized by a moderate threat of substitutes. While there are alternative products and services available, they are not perfect substitutes, and ConvaTec's products have a unique value proposition.

Bargaining Power Of Customers

ConvaTec Group Plc's customers are primarily healthcare providers and patients, who have limited bargaining power due to the specialized nature of ConvaTec's products and services.

Bargaining Power Of Suppliers

ConvaTec Group Plc's suppliers are primarily manufacturers of raw materials and components, who have some bargaining power due to the specialized nature of their products. However, ConvaTec's scale and diversification mitigate this power.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including regulatory hurdles and significant research and development investments, which limit the threat of new entrants.

Intensity Of Rivalry

The medical technology industry is highly competitive, with several established players competing for market share. ConvaTec Group Plc faces intense competition from companies such as Johnson & Johnson, Medtronic, and 3M.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 43.67%
Debt Cost 6.94%
Equity Weight 56.33%
Equity Cost 6.94%
WACC 6.94%
Leverage 77.53%

11. Quality Control: ConvaTec Group Plc passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fielmann

A-Score: 5.9/10

Value: 4.4

Growth: 5.0

Quality: 7.3

Yield: 4.4

Momentum: 6.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
ConvaTec

A-Score: 4.8/10

Value: 2.8

Growth: 5.3

Quality: 6.0

Yield: 3.1

Momentum: 5.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Ypsomed

A-Score: 4.1/10

Value: 2.6

Growth: 8.2

Quality: 5.7

Yield: 0.6

Momentum: 3.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Tecan

A-Score: 3.9/10

Value: 4.9

Growth: 4.1

Quality: 6.1

Yield: 2.5

Momentum: 1.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Elekta

A-Score: 3.4/10

Value: 3.8

Growth: 4.0

Quality: 3.2

Yield: 6.9

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Amplifon

A-Score: 3.4/10

Value: 5.0

Growth: 5.4

Quality: 4.7

Yield: 2.5

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.37$

Current Price

2.37$

Potential

-0.00%

Expected Cash-Flows